JPH09301879A - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- JPH09301879A JPH09301879A JP8118860A JP11886096A JPH09301879A JP H09301879 A JPH09301879 A JP H09301879A JP 8118860 A JP8118860 A JP 8118860A JP 11886096 A JP11886096 A JP 11886096A JP H09301879 A JPH09301879 A JP H09301879A
- Authority
- JP
- Japan
- Prior art keywords
- antacid
- sofalcone
- pharmaceutical composition
- day
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 18
- 229940069428 antacid Drugs 0.000 claims abstract description 12
- 239000003159 antacid agent Substances 0.000 claims abstract description 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 10
- 230000001458 anti-acid effect Effects 0.000 claims abstract description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- PGZIKUPSQINGKT-UHFFFAOYSA-N dialuminum;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PGZIKUPSQINGKT-UHFFFAOYSA-N 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 208000016752 upper digestive tract disease Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 abstract description 10
- GFWRVVCDTLRWPK-KPKJPENVSA-N sofalcone Chemical compound C1=CC(OCC=C(C)C)=CC=C1\C=C\C(=O)C1=CC=C(OCC=C(C)C)C=C1OCC(O)=O GFWRVVCDTLRWPK-KPKJPENVSA-N 0.000 abstract description 8
- 229950004782 sofalcone Drugs 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 210000002784 stomach Anatomy 0.000 abstract description 4
- 210000004211 gastric acid Anatomy 0.000 abstract description 3
- -1 magnesium silicate aluminate Chemical class 0.000 abstract description 3
- 230000003472 neutralizing effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 241000242873 Scopolia Species 0.000 abstract 2
- 229910052919 magnesium silicate Inorganic materials 0.000 abstract 2
- 235000019792 magnesium silicate Nutrition 0.000 abstract 2
- 239000000391 magnesium silicate Substances 0.000 abstract 2
- 238000004904 shortening Methods 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NGQJIEUOZYTRPF-UHFFFAOYSA-N 3-[2-(3-methylbuta-1,3-dienyl)phenyl]-1-phenylprop-2-en-1-one Chemical class CC(=C)C=CC1=CC=CC=C1C=CC(=O)C1=CC=CC=C1 NGQJIEUOZYTRPF-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、医薬組成物に関す
る。TECHNICAL FIELD The present invention relates to a pharmaceutical composition.
【０００２】[0002]
【従来の技術】近年、社会生活におけるストレスの増加
や食事習慣の変化などにより、胃炎、胃潰瘍などの上部
消化管疾患の患者が増加している。その治療剤として種
々の薬剤が開発されており、代表的なものとしてソファ
ルコンをあげることができる。ソファルコンは広豆根の
研究から開発されたイソプレニルカルコン誘導体であ
り、化学名は２’−カルボキシメトキシ−４，４’−ビ
ス（３−メチル−２−ブテニルオキシ）カルコンと称
し、その配合製剤が特開平７−１７９３４６号公報、特
開平４−１１２８２４号公報などに記載されている。し
かしながら、従来知られているソファルコン配合剤は疾
病の治療に対して必ずしも満足できるものではなかっ
た。2. Description of the Related Art In recent years, the number of patients with upper gastrointestinal tract diseases such as gastritis and gastric ulcer has been increasing due to an increase in stress in social life and changes in dietary habits. Various drugs have been developed as the therapeutic agent, and a typical example thereof is sofa lucone. Sofalcon is an isoprenyl chalcone derivative developed from the study of broad roots, the chemical name is 2'-carboxymethoxy-4,4'-bis (3-methyl-2-butenyloxy) chalcone, and its combination preparation. Are described in JP-A-7-179346 and JP-A-4-112824. However, the conventionally known Sofalcone combination agents have not always been satisfactory for treating diseases.
【０００３】[0003]
【発明が解決しようとする課題】本発明は、ソファルコ
ンを配合した製剤による、各種疾病の治療期間の短縮を
目的とする。DISCLOSURE OF THE INVENTION The present invention aims to shorten the treatment period for various diseases by using a preparation containing sofa lucone.
【０００４】[0004]
【課題を解決するための手段】本発明者らは上記事情を
鑑み種々検討した結果、ソファルコン、ロートエキスお
よび制酸剤を配合した医薬組成物が胃炎の治療期間を大
幅に短縮することを見いだし本発明を完成した。すなわ
ち本発明はソファルコン、ロートエキスおよび制酸剤か
らなる医薬組成物である。Means for Solving the Problems As a result of various investigations in view of the above circumstances, the present inventors have found that a pharmaceutical composition containing sofa lucone, a funnel extract, and an antacid significantly shortens the period for treating gastritis. Found and completed the present invention. That is, the present invention is a pharmaceutical composition comprising sofa lucone, a funnel extract and an antacid.
【０００５】[0005]
【発明の実施の形態】本発明においてロートエキスとは
ロートコンを常法により抽出したものもしくはその乾燥
物などである。制酸剤とは炭酸水素ナトリウム、ケイ酸
アルミン酸マグネシウム、リン酸水素カルシウム、メタ
ケイ酸アルミン酸ナトリウム、合成ヒドロタルサイトな
どをあげることができるが、好ましいものとして炭酸水
素ナトリウムおよびケイ酸アルミン酸マグネシウムをあ
げることができる。制酸剤は２種以上を用いてもよく、
特に速効的な胃酸中和作用を有する薬剤と持続的な胃酸
中和作用を有する薬剤を併用すると胃炎の治療効果の点
で好ましい。特に、炭酸水素ナトリウムおよびケイ酸ア
ルミン酸マグネシウムを同時配合すると胃炎治療効果の
点で最も好ましい。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, the roto extract is a product obtained by extracting rotocon by a conventional method or a dried product thereof. Examples of the antacid include sodium hydrogencarbonate, magnesium aluminate silicate, calcium hydrogenphosphate, sodium aluminometasilicate, synthetic hydrotalcite, and the like, with preference given to sodium hydrogencarbonate and magnesium aluminate silicate. Can be raised. Two or more antacids may be used,
In particular, it is preferable to use a drug having a fast-acting gastric acid-neutralizing action in combination with a drug having a persistent gastric-acid neutralizing action in terms of the therapeutic effect on gastritis. In particular, simultaneous blending of sodium hydrogen carbonate and magnesium aluminate silicate is most preferable from the viewpoint of therapeutic effect on gastritis.
【０００６】各配合成分はソファルコン１重量部に対し
て、ロートエキスの乾燥物換算で０．０１〜５重量部、
好ましくは０．０５〜２重量部、最も好ましくは０．１
重量部である。また、制酸剤の量は、胃内のｐＨを３〜
５に保持するのに充分な量が好ましい。制酸剤として炭
酸水素ナトリウムおよびケイ酸アルミン酸マグネシウム
を用いた場合の配合量は、１日３回投与の場合、１回分
で炭酸水素ナトリウム５０〜２０００ｍｇ、好ましくは
１００〜５００ｍｇ、最も好ましくは２００ｍｇであ
り、ケイ酸アルミン酸マグネシウムは５０〜１５００ｍ
ｇ、好ましくは１５０〜５００ｍｇ、最も好ましくは３
００ｍｇである。[0006] Each blending component is 0.01 to 5 parts by weight in terms of a dried product of the funnel extract, relative to 1 part by weight of Sofalcone
Preferably 0.05 to 2 parts by weight, most preferably 0.1.
Parts by weight. Also, the amount of antacid should be adjusted to pH in the stomach of 3 to
A sufficient amount to hold at 5 is preferred. When sodium hydrogen carbonate and magnesium aluminate silicate are used as antacids, the dosage is 50 to 2000 mg, preferably 100 to 500 mg, and most preferably 200 mg of sodium bicarbonate per administration when administered three times a day. And magnesium aluminate silicate is 50-1500 m
g, preferably 150-500 mg, most preferably 3
00 mg.
【０００７】本発明の医薬組成物を胃炎の治療に用いた
場合、通常、成人に対して１日あたり１回〜数回に分け
て経口または非経口で投与することができる。ソファル
コンの投与量は１０〜１０００ｍｇ／日が好ましい。こ
の投与量は年齢、体重、病状などにより適宜増減するこ
とができる。When the pharmaceutical composition of the present invention is used for treating gastritis, it can be usually orally or parenterally administered to an adult once to several times a day. The dose of sofalcon is preferably 10 to 1000 mg / day. This dose can be appropriately increased or decreased depending on the age, body weight, medical condition and the like.
【０００８】本発明の医薬は、錠剤、顆粒剤、散剤、カ
プセル剤、液剤など経口投与形態または注射剤、塗布剤
などの非経口投与形態の通常の製剤として用いる。The drug of the present invention is used as a usual preparation in an oral dosage form such as tablets, granules, powders, capsules, solutions or parenteral dosage forms such as injections and coatings.
【０００９】これらの製剤は、常法により調製すること
ができる。製剤の調製に使用する担体としては、乳糖、
デンプン、砂糖、マンニトール、結晶セルロースなどの
賦形剤、ヒドロキシプロピルセルロース、ヒドロキシプ
ロピルメチルセルロース、ゼラチン、ポリビニルピロリ
ドンなどの結合剤、カルボキシメチルセルロースカルシ
ウム、低置換度ヒドロキシプロピルセルロースなどの崩
壊剤、ステアリン酸マグネシウム、硬化ヒマシ油、タル
クなどの滑択剤があり、この他必要に応じて溶解補助
剤、緩衝剤、保存剤、香料、色素、矯味剤などを使用す
ることができる。These formulations can be prepared by a conventional method. Carriers used in the preparation of formulations include lactose,
Excipients such as starch, sugar, mannitol, crystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, gelatin, binders such as polyvinylpyrrolidone, carboxymethylcellulose calcium, disintegrating agents such as low-substituted hydroxypropylcellulose, magnesium stearate, There are lubricants such as hydrogenated castor oil and talc, and if necessary, solubilizing agents, buffers, preservatives, perfumes, dyes, flavoring agents and the like can be used.
【００１０】[0010]
【実施例】以下に実施例および試験例により本発明をさ
らに詳細に説明する。The present invention will be described in more detail with reference to the following examples and test examples.
【００１１】実施例１ ソファルコン ３００ｍｇ、ロートエキス３倍散 ９０
ｍｇ、炭酸水素ナトリウム ６００ｍｇおよびケイ酸ア
ルミン酸マグネシウム ９００ｍｇをとり、日本薬局方
製剤総則、散剤の項の製法に準じ調製し、３分包して散
剤を得た。Example 1 Sofalcon 300 mg, funnel extract 3 times 90
mg, sodium hydrogencarbonate 600 mg and magnesium aluminate silicate 900 mg were prepared according to the manufacturing method of the Japanese Pharmacopoeia General Formulation, Powder Section, and packaged for 3 minutes to obtain a powder.
【００１２】試験例 実施例１で調製した散剤を１６５名（男性７５例、女性
９０例、平均年齢４７．１歳）の胃炎患者に１回１包、
１日３回経口投与して自覚症状（胃痛、胃部不快感、胃
重感、胃部膨満感、胃もたれ、はきけ、胸やけ、げっ
ぷ、胸のつかえ）の改善度を見た。総合改善度をソファ
ルコンのみの製剤についての文献（診療と新薬、第２３
巻、２６１９−２６３１頁、１９８６年）に記載のデー
タと比較した。実施例、比較データともソファルコンの
含有量は１包あたり１００ｍｇで同一である。Test Example The powder prepared in Example 1 was packaged once for 165 patients (75 men, 90 women, average age 47.1 years) with gastritis,
Oral administration was carried out three times a day, and the degree of improvement in subjective symptoms (stomach pain, stomach discomfort, stomach sensation, gastric bloating, stomach lean, brush, heartburn, belching, chest tightness) was observed. The total improvement is described in the literature on the preparation of Sofalcone only (medical care and new drugs, No. 23).
Vol. 2619-2631, 1986). The content of sofa lucone was the same in each of the Examples and Comparative Data, 100 mg per package.
【００１３】結果 自覚症状の中等度以上の改善度は実施例１記載の散剤は
２週間投与で８８．４％であった。文献記載データでは
４週間投与でも８０．５％である。このことから本発明
の医薬組成物は従来技術と比較し、胃炎治療期間の短縮
を図っていることが明らかに解る。Results The moderate or higher degree of improvement in subjective symptoms was 88.4% when the powder described in Example 1 was administered for 2 weeks. According to the data described in the literature, it is 80.5% even after administration for 4 weeks. From this, it is clear that the pharmaceutical composition of the present invention is intended to shorten the period for treating gastritis, as compared with the prior art.
【００１４】[0014]
【発明の効果】上記試験例から明らかなように、本発明
によりソファルコンを投与した胃炎患者の治療期間を短
縮することが可能になった。また、ソファルコンが有効
なその他の疾病の治療期間を短縮することが可能になっ
た。EFFECTS OF THE INVENTION As is clear from the above-mentioned test examples, the present invention makes it possible to shorten the treatment period of gastritis patients to whom sofarcone was administered. In addition, it has become possible to shorten the treatment period for other diseases for which Sofalucon is effective.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 //(Ａ６１Ｋ 31/19 35:78 33:06 33:00） (72)発明者 恒成 嘉伸 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification number Office reference number FI technical display location // (A61K 31/19 35:78 33:06 33:00) (72) Inventor Koshinari Yoshinobu 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd.
Claims (3)
剤を配合することを特徴とする医薬組成物。1. A pharmaceutical composition comprising sofalcon, a funnel extract and an antacid.
載の医薬組成物。2. The pharmaceutical composition according to claim 1, which is a therapeutic agent for upper gastrointestinal tract diseases.
ムおよび炭酸水素ナトリウムである請求項１または２に
記載の医薬組成物。3. The pharmaceutical composition according to claim 1, wherein the antacid is magnesium aluminate silicate and sodium hydrogen carbonate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11886096A JP4726268B2 (en) | 1996-05-14 | 1996-05-14 | Pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11886096A JP4726268B2 (en) | 1996-05-14 | 1996-05-14 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09301879A true JPH09301879A (en) | 1997-11-25 |
| JP4726268B2 JP4726268B2 (en) | 2011-07-20 |
Family
ID=14746933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11886096A Expired - Lifetime JP4726268B2 (en) | 1996-05-14 | 1996-05-14 | Pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4726268B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058552A (en) * | 2010-12-22 | 2011-05-18 | 天津药物研究院药业有限责任公司 | Sofalcone sustained release tablet and preparation method thereof |
-
1996
- 1996-05-14 JP JP11886096A patent/JP4726268B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058552A (en) * | 2010-12-22 | 2011-05-18 | 天津药物研究院药业有限责任公司 | Sofalcone sustained release tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4726268B2 (en) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5156845A (en) | Dry mouth lozenge | |
| TW576743B (en) | Extended release formulations of erythromycin derivatives | |
| JP3977724B2 (en) | Pharmaceutical composition | |
| KR20000052950A (en) | Chewing gum containing colloidal bismuth subcitrate | |
| JPH07502527A (en) | Compositions containing low doses of histamine-H2-receptor antagonists | |
| US5661171A (en) | Controlled release pilocarpine delivery system | |
| JPS63313726A (en) | Method and composition for treating nervous disease such as hemicrania by stimulating nervous cell | |
| RU2762754C2 (en) | Composition applicable in prevention and/or treatment of oral and gastrointestinal mucositis induced by oncological treatment | |
| JPH08259445A (en) | Medicinal composition for improving gastric emptying performance | |
| RU2126249C1 (en) | Pharmaceutical composition for oral administration for treatment of patients with pathology of gastroenteric tract upper regions | |
| De Conno et al. | Oral complications in patients with advanced cancer | |
| AU1835201A (en) | Treatment of fibromyalgia with Ubiquinone 10 and succinic acid | |
| RU2261098C2 (en) | Mirtazapine-containing orally decomposing composition | |
| JP2001518481A (en) | Serotonin-containing preparations for oral administration and methods of use | |
| JPS6393710A (en) | Slow release fluoride composition | |
| JPH01261334A (en) | Medical preparation containing angiotensine invertase inhibitor as effective component and production thereof | |
| JPH09301879A (en) | Pharmaceutical composition | |
| JPH07126163A (en) | Controllably releasable pilocarpine transmitting system | |
| Dekker et al. | An international multi-clinic study comparing the therapeutic efficacy of colloidal bismuth subcitrate coated tablets with chewing tablets in the treatment of duodenal ulceration | |
| US5216019A (en) | Pain killer | |
| US20070053930A1 (en) | Combination therapy for treatment of high cholesterol | |
| WO1994001108A1 (en) | Controlled release pilocarpine delivery system | |
| JP3937448B2 (en) | H. Use of spiramycin for the treatment of gastrointestinal disorders caused by Pylori | |
| RU2354378C1 (en) | Combined anti-tuberculosis preparation | |
| Westergren et al. | Effective once-daily treatment of hypertension with low-dose, controlled-release metoprolol: pooled results from three randomized, double-blind, placebo-controlled studies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070717 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070913 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070913 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070918 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080222 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110218 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110412 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140422 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140422 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |